Floatz logo

Irinotecan

Regorafenib

Sun Yat-sen UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Regorafenib cohort.

Asset / SponsorPhaseRating
Regorafenib
M.D. Anderson Cancer Center
Phase 3BB
Lorigerlimab
M.D. Anderson Cancer Center
Phase 2CCC
Raltitrexed
China Medical University, China
Phase 1/2CC
Iparomlimab
JIANG LONGWEI
Early Phase 1C
Tuvonralimab
JIANG LONGWEI
Early Phase 1C

View all 9 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →